Jasper Therapeutics (JSPR) PT Lowered to $6 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts JSPR Hot Sheet
Price: $0.48 --0%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Cantor Fitzgerald analyst Pete Stavropoulos lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $6.00 (from $10.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Jasper Therapeutics enacts 1-for-30 reverse stock split
- Hybe Corporation (352820:KS) PT Lowered to KRW250,000 at Citi
- Bharat Electronics Ltd (BHE:IN) PT Lowered to INR470 at Axis Capital Limited
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
